Core Viewpoint - Investors are evaluating IQVIA Holdings (IQV) and Waters (WAT) for potential undervalued stock opportunities, with IQV currently appearing as the more favorable option based on various valuation metrics [1]. Valuation Metrics - IQV has a forward P/E ratio of 22.16, while WAT has a higher forward P/E of 25.97, indicating that IQV may be more attractively priced [3]. - The PEG ratio for IQV is 2.05, compared to WAT's PEG ratio of 4.90, suggesting that IQV's expected earnings growth is more reasonably priced [3]. - IQV holds a Value grade of B, while WAT has a Value grade of D, reflecting stronger estimate revision activity and more attractive valuation metrics for IQV [4]. Zacks Rank and Style Scores - IQV has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while WAT has a Zacks Rank of 4 (Sell) [2]. - The Zacks Rank system favors stocks with strong earnings estimate revisions, and combining this with a strong Value grade can help identify great value stocks [5]. Additional Valuation Comparisons - IQV's P/B ratio is 6.65, significantly lower than WAT's P/B ratio of 14.50, further indicating that IQV may be undervalued relative to its book value [6]. - The Value category of the Style Scores system utilizes various metrics, including P/E ratio, P/S ratio, earnings yield, and cash flow per share, to assess a company's fair value [7].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35907 _____________________________________________________ ...

Life sciences clinical researcher IQVIA's second-quarter results beat analysts' expectations for revenue and net income. The company also raised its full-year guidance. IQVIA said its technology and analytics products were major growth drivers. IQVIA's stock rose nearly 7% in intraday trading Monday to move into positive territory for the year. Growth Driven by Technology & Analytics Solutions Unit Looking ahead, IQVIA narrowed its full-year revenue guidance to a range of $15.43 billion to $15.53 billion fr ...

Company Performance - IQV stock has gained 5.2% over the past six months, outperforming the industry rally of 2.9% [1] - IQVIA Holdings Analytics Inc. reported impressive second-quarter 2024 results, with earnings and revenues surpassing the Zacks Consensus Estimate [12] - Adjusted earnings were $2.6 per share, exceeding the Zacks Consensus Estimate by 2.3% and increasing 2.4% year-over-year [6] - Total revenues reached $3.8 billion, slightly surpassing the consensus estimate and rising 2.3% from the previous year [6] - Adjusted EBITDA for the second quarter was $887 million, indicating a 12.7% growth from the year-ago quarter [8] Revenue Segments - Research and Development segment revenues were $2.2 billion, increasing 2.4% from the year-ago quarter and 3.3% on a constant-currency basis, surpassing the estimate of $2.1 billion [2] - Technology and Analytics segment revenues were $1.5 billion, increasing 2.7% from the second quarter of 2023, meeting the estimate and increasing 3.8% on a constant-currency basis [7] - Contract Sales & Medical Solutions revenues declined 2.3% year-over-year to $172 million, missing the estimate of $177 million but increasing 2.8% on a constant-currency basis [13] Financial Position - The company exited the quarter with cash and cash equivalents of $1.5 billion, up from $1.4 billion at the end of the previous quarter [3] - Long-term debt decreased to $12.1 billion from $12.8 billion at the end of the first quarter of 2024 [3] - Net cash generated from operating activities was $588 million, with capital expenditure of $143 million, resulting in a free cash flow of $445 million for the quarter [14] Guidance - For 2024, IQV updated its revenue guidance to $15.43-$15.53 billion, with the mid-point of $15.48 billion higher than the Zacks Consensus Estimate of $15.44 billion [4] - The adjusted EPS guidance was raised to $11.10-$11.30, compared to the previous range of $10.95-$11.25, with the Zacks Consensus Estimate at $11.07 [15] - The updated guided range for adjusted EBITDA is anticipated to be $3.71-$3.77 billion, compared to the previous range of $3.70-$3.80 billion [15]

Company Performance - IQVIA reported quarterly earnings of $2.64 per share, exceeding the Zacks Consensus Estimate of $2.58 per share, and up from $2.43 per share a year ago [9] - The company posted revenues of $3.81 billion for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.69%, and compared to revenues of $3.73 billion in the same quarter last year [4] - IQVIA has surpassed consensus EPS estimates four times over the last four quarters [10] Market Comparison - IQVIA shares have declined approximately 2.9% since the beginning of the year, while the S&P 500 has gained 15.4% [5] - The Zacks Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [12] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $2.81 on revenues of $3.86 billion, and for the current fiscal year, it is $11.07 on revenues of $15.44 billion [7] - The estimate revisions trend for IQVIA is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6][11]

IQVIA Reports Second-Quarter 2024 Results RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE) – July 22, 2024 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2024. Revenue for the second quarter of $3,814 million increased 2.3 percent on a reported basis and 3.5 percent at constant currency, compared to the second quarter ...

Q2 Expectations The Research and Development segment's revenues are expected to be $2.1 billion, implying a 1.7% rise from the year-ago reported figure.The top 10 pharmaceutical companies chose IQVIA to support the novel respiratory vaccine development, which could lead to a breakthrough as the vaccine targets several respiratory viruses simultaneously. Such a feat is anticipated to have benefited this segment's revenues.Our estimate for Contract sales and Medical solutions' revenues is pegged at $177 milli ...

IQV has reported impressive first-quarter 2024 results. Adjusted earnings (excluding 98 cents from nonrecurring items) were $2.5 per share, which beat the Zacks Consensus Estimate by 2.8% and increased 3.7% from the year-ago reported figure. Total revenues of $3.7 billion surpassed the consensus estimate by 1.2% and grew 2.3% from the year-ago quarter. The company's addressable market size is more than $330 billion. It consists of outsourced research and development, real-world evidence and connected health ...

IQVIA Holdings Inc. (IQV) yesterday unveiled a clinical trial technology platform, One Home for Sites. The platform streamlines the process of management of trials by acting as a single sign-on and a single dashboard for various systems and tasks. By integrating various clinical applications into a single platform, One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management. This consolidation tackles the issue of technology overload, where sta ...

Last time, I commented on the company's strengths in unlocking risk capital for shareholders, namely via 1) exceptional net operating profit after tax relative to the capital invested to produce these numbers, 2) decompression of post-tax margins with increasing capital turnover, and 3) the company's propensity to throw off stable, high amounts of free cash flow to its owners. Figure 1. IQV price evolution, 12 months Seeking Alpha You can check out a deeper analysis on what the company does, its business li ...